Skip to main content
GutCited

Bifidobacterium lactis per Chronic Constipation

B

Dose-dependently reduces whole gut transit time (WGTT). Higher dose (17.2 billion CFU) showed 31% reduction in WGTT. Also reduces functional GI symptoms.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dlactis\u0026condition\u003Dconstipation'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

In sintesi

Dose-dependently reduces whole gut transit time (WGTT). Higher dose (17.2 billion CFU) showed 31% reduction in WGTT. Also reduces functional GI symptoms.

Key Study Findings

Randomized Controlled Trial 8 weeks Double-blind
Effect of an 8-Week Bifidobacterium lactis HN019 Supplementation on Functional Constipation: A Multi-Center, Triple-Blind, Randomized, …
Dose: None vs: Placebo Outcome: Complete spontaneous bowel movements (CSBMs) Effetto: None None

Popolazione: Adults with functional constipation (Rome III)

Randomized Controlled Trial n=67 4 weeks Double-blind
Effects and Persistence of Bifidobacterium animalis subsp. lactis BL-99 and Fructooligosaccharides on Older Adults with …
Dose: None vs: Placebo Outcome: Weekly spontaneous bowel movements Effetto: 4.94 vs 3.00 (P<0.001) P<0.001

Popolazione: Older adults >=60 with functional constipation (Rome IV)

Randomized Controlled Trial n=35 12 weeks Double-blind
Multistrain Probiotics Plus Vitamin D Improve Gut Barrier Function and Gut Microbiota Composition in Irritable …
Dose: None vs: Placebo Outcome: Gut barrier function (zonulin levels) Effetto: Zonulin -19.5 ng/mL at week 16 p=0.0002 wk16; p=0.0053 grp

Popolazione: IBS without constipation patients

Review
An update on probiotics in paediatrics.
Dose: None vs: None Outcome: GI disorder outcomes in paediatrics Effetto: None None

Popolazione: Paediatric patients with GI disorders

In Vitro n=35
A Probiotic Mixture of Lactobacillus rhamnosus LR 32, Bifidobacterium lactis BL 04, and Bifidobacterium longum …
Dose: 1e6 CFU/mL vs: IBS supernatants without probiotic Outcome: Caco-2 paracellular permeability Effetto: None <0.001

Popolazione: IBS patients (28) and asymptomatic controls (7)

Randomized Controlled Trial n=128 2 weeks Double-blind
Probiotics and Fever Duration in Children With Upper Respiratory Tract Infections: A Randomized Clinical Trial.
Dose: 0.5 mL daily for 14 days vs: Placebo Outcome: Fever duration (days) Effetto: RR 0.64 (95% CI 0.51-0.80) None

Popolazione: Children 28 days-4 years with fever and URTI

Key Statistics

4

Studi

600

Partecipanti

Positive

B

Grado

Referenced Papers

Current opinion in … 2025
Pediatric gastroenterology, hepatology … 2017 27 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
1-10 billion CFU/day
immunesupport:
5-10 billion CFU/day
constipationsupport:
17.2 billion CFU/day (HN019 strain, optimal dose)

Limite massimo: Well-tolerated up to 17.2 billion CFU/day in clinical trials

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None 8 weeks Neutral --
None 4 weeks Positive 67
None 12 weeks Positive 35
None -- Positive --
1e6 CFU/mL -- Positive 35
0.5 mL daily for 14 days 2 weeks Positive 128
None 2 weeks Negative 117
10 g 4 weeks Positive --

Momento migliore per l'assunzione: With or without food; morning dosing may be optimal for transit effects

Safety & Side Effects

Effetti collaterali segnalati

  • Mild gas and bloating during initial use
  • Occasional abdominal discomfort
  • Rare loose stools
  • Very rare: bacteremia in immunocompromised individuals

Interazioni note

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (use with caution in immunocompromised patients)

Livello di assunzione massimo tollerabile: Well-tolerated up to 17.2 billion CFU/day in clinical trials

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Bifidobacterium lactis help with Chronic Constipation?
Based on 4 studies with 600 participants, there is moderate evidence from clinical studies that Bifidobacterium lactis may support Chronic Constipation management. Our evidence grade is B (Good Evidence).
How much Bifidobacterium lactis should I take for Chronic Constipation?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bifidobacterium lactis?
Reported side effects may include Mild gas and bloating during initial use, Occasional abdominal discomfort, Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bifidobacterium lactis and Chronic Constipation?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 600 total participants. The overall direction of effect is positive.

Related Evidence

Altri ingredienti per Chronic Constipation

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.